GMP CAR-T cell production
- PMID: 29909913
- DOI: 10.1016/j.beha.2018.01.002
GMP CAR-T cell production
Abstract
The clinical success achieved using CD19-directed CAR-T cells has stimulated many academic institutions to explore the feasibility of manufacturing these, and other CAR-T cells, in-house. This article reviews the issues that must be addressed in order to achieve this goal. It includes the manufacturing infrastructure, the regulatory environment, practical aspects of production, and the costs involved.
Keywords: CAR-T cells; Good manufacturing practices; Manufacturing.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources